Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILI trial of metformin for cancer risk reduction in Li-Fraumeni syndrome
ISRCTN16699730Phase 2Recruiting
- Sponsor
- University of Oxford
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of metformin in Li-Fraumeni syndrome (LFS) (2 arms), sponsored by University of Oxford. Primary endpoint: Cancer-free survival. Started Dec 2023; status: recruiting.
02
Drugs
metformin
03
Conditions
Li-Fraumeni syndrome (LFS)
Beyond the preview
Go deeper on ISRCTN16699730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16699730.